XtalPi
An AI-, quantum-physics- and high-performance-computing company that provides drug-discovery and materials-science technologies.
Last updated October 30, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
XtalPi, also known as XtalPi Holdings Limited and 晶泰科技, is a Chinese biotechnology and computational-science company focused on early-stage drug discovery and materials science. Its platform combines quantum chemistry, quantum-physics-based computation, machine learning, artificial intelligence, high-performance computing and laboratory automation. The company primarily operates as a technology and research partner for pharmaceutical and industrial customers rather than as a conventional drug manufacturer with a large internally owned clinical pipeline. XtalPi was founded in China in 2015 by Wen Shuhao, Ma Jian and Lai Lipeng, three quantum physicists who had previously worked as postdoctoral researchers at the Massachusetts Institute of Technology. The founders applied computational methods to problems in molecular modeling and drug development. This positioning placed XtalPi among the early Asian companies attempting to commercialize AI-assisted drug discovery, a field that attracted substantial attention from pharmaceutical companies and technology investors. Reported investors have included Tencent, 5Y Capital, Google, Susquehanna International Group, Sino Biopharmaceutical and SoftBank Vision Fund. The company’s drug-discovery approach uses quantum-chemical calculations to generate and analyze molecular data. Machine-learning systems use these datasets to model molecular properties, search very large chemical spaces and propose compounds with potentially useful characteristics. Candidate molecules can then be assessed through automated or robotic experimentation in XtalPi facilities in China and the United States. Its services include molecular design, virtual screening, property prediction, crystal-form prediction and other computational or experimental tools intended to shorten the early stages of pharmaceutical research. XtalPi’s business model emphasizes collaboration with established pharmaceutical companies. Reported customers and partners have included Eli Lilly, Johnson & Johnson, Merck & Co. and Pfizer. In 2016, the company participated in a Pfizer blind test concerning the prediction of three-dimensional molecular structures and was reported to have achieved complete accuracy in that exercise. The result contributed to a reported 10-year Pfizer partnership in early-stage drug discovery. During the COVID-19 pandemic, XtalPi also assisted work connected with the development of Pfizer’s oral antiviral Paxlovid. These collaborations helped establish the company as a computational and laboratory-services provider rather than a direct substitute for the full pharmaceutical-development process. The company has acknowledged or pursued a broader technology scope beyond pharmaceuticals. From around 2022, it expanded its materials-science activities, applying computational discovery and experimentation to areas such as solar-panel materials and electric-vehicle batteries. Perovskite materials have been a notable focus because of their potential to improve solar-cell efficiency, although their manufacturing and scale-up remain challenging. Materials applications can offer shorter commercialization cycles than medicines because they do not require the same sequence of human clinical trials. XtalPi completed an initial public offering in Hong Kong in June 2024 under the exchange’s Chapter 18C regime for specialist technology companies. The offering reportedly raised HK$989.3 million. In February 2025, the company announced a proposed HK$2.08 billion share placement and a cooperation arrangement involving a subsidiary and Hengjian Holding for an AI-and-technology industrial-integration project in the Greater Bay Area. In April 2025, during a visit by Xi Jinping to Shanghai, XtalPi presented its commitment to scientific and technological self-reliance. In August 2025, it announced a reported US$6 billion agreement with DoveTree, a firm established by Gregory L. Verdine. In April 2026, its AI-biotech subsidiary Ailux appointed Maria Belvisi as chief scientific officer, according to the supplied reference material. XtalPi’s commercial appeal lies in its ability to integrate computation, software, data and automated experiments for research organizations that want to increase the speed and breadth of early discovery. Its limitations are also characteristic of the sector: promising computational predictions still require laboratory validation, toxicology, clinical trials and regulatory approval. Commentators have questioned whether AI-assisted discovery can reliably address the most difficult parts of drug development, particularly work in human subjects, which XtalPi generally does not undertake itself. The company therefore occupies a position between software, contract research, laboratory automation and biotechnology, with its long-term prospects tied to the reproducibility of its platforms and the commercial success of customer programs. The company has acknowledged or pursued a broader technological scope beyond pharmaceuticals. Beginning around 2022, it expanded materials-science activities, applying computational discovery and experimentation to areas such as solar-panel materials and electric-vehicle batteries. Perovskite materials became a notable focus because of their potential to improve solar-cell efficiency, although manufacturing and scale-up remain challenging. Materials applications have shorter commercialization cycles than medicines because they do not require the same sequence of human clinical trials. In August 2024, GCL-Poly was reported to have agreed to pay XtalPi more than US$135 million for upgrades involving perovskite and electric-vehicle-battery materials. The principal debate around XtalPi and similar companies concerns the boundary between computational promise and validated pharmaceutical outcomes. AI can help prioritize compounds and improve some parts of discovery, but predictions still require laboratory testing, toxicology, clinical trials and regulatory review. Commentators including Derek Lowe have questioned whether computational systems address the most difficult portion of drug development, especially work involving humans. XtalPi’s history therefore reflects both the growth of AI-enabled biotechnology and the continuing importance of experimental and clinical validation.
History
XtalPi was founded in China in 2015 by Wen Shuhao, Ma Jian and Lai Lipeng. The three founders were quantum physicists who had previously undertaken postdoctoral research at the Massachusetts Institute of Technology. They established the company around the idea that quantum-physics-based computation, combined with machine learning and substantial computing capacity, could improve the speed and precision of early drug discovery. The company entered a market in which pharmaceutical research was increasingly using computational methods to reduce the cost and time of identifying promising molecules. XtalPi developed systems that use quantum-chemical calculations to model molecular structures and properties. The resulting datasets can be used to train machine-learning models, which then search large chemical spaces and propose compounds for further investigation. The company complemented its computational work with automated laboratory testing in China and the United States. XtalPi attracted investment from major technology, pharmaceutical and financial investors, including Tencent, 5Y Capital, Google, Susquehanna International Group, Sino Biopharmaceutical and SoftBank Vision Fund. Its early customer and collaboration base included Eli Lilly, Johnson & Johnson, Merck & Co. and Pfizer. In 2016, XtalPi participated in a Pfizer blind test involving prediction of the three-dimensional structures of molecules relevant to drug activity. The company was reported to have achieved complete accuracy in the exercise, after which it received a reported 10-year partnership for early-stage drug discovery. During the COVID-19 pandemic, the company was also involved in work supporting the development of Pfizer’s Paxlovid. XtalPi does not generally present itself as a traditional pharmaceutical company that discovers, clinically tests and commercializes a broad portfolio of proprietary medicines from beginning to end. Instead, it supplies computational platforms, modeling, design, screening and experimental services to pharmaceutical customers. This arrangement lets the company concentrate on technology development and avoid much of the financial and clinical risk borne by drug manufacturers. It also means that its commercial value depends on customer adoption, the quality of its predictions and the eventual progress of customer programs. Beginning around 2022, XtalPi expanded into materials science. The company identified materials research as an area where computational discovery could address industrial problems and where commercialization may be faster than in medicine, which must pass through lengthy human trials. Its reported areas of interest have included perovskite materials for solar panels and materials used in electric-vehicle batteries. Perovskites can potentially improve photovoltaic performance, but their practical deployment requires solutions to manufacturing, stability and scale-up challenges. In August 2024, GCL-Poly was reported to have agreed to pay XtalPi more than US$135 million for upgrades involving perovskite and electric-vehicle-battery materials. In June 2024, XtalPi completed an initial public offering on the Hong Kong Stock Exchange. The listing used the exchange’s Chapter 18C framework for specialist technology companies, and was described in the supplied reference as the first listing under that rule. The offering reportedly raised HK$989.3 million. In February 2025, XtalPi announced a proposed HK$2.08 billion share placement and a cooperation arrangement involving Hengjian Holding for an AI and technology industrial-integration consortium project in the Greater Bay Area. The company also became associated with national technology-policy messaging. In April 2025, during Xi Jinping’s visit to Shanghai, XtalPi participated in a meeting presenting its commitment to scientific and technological self-reliance. In August 2025, it announced a reported US$6 billion agreement with DoveTree, a company established by Gregory L. Verdine. In April 2026, Ailux, identified in the supplied reference as an XtalPi AI-biotech subsidiary, appointed Maria Belvisi as chief scientific officer. The principal debate around XtalPi and similar companies concerns the boundary between computational promise and validated pharmaceutical outcomes. AI can help prioritize compounds and improve some parts of discovery, but predictions still require laboratory testing, toxicology, clinical trials and regulatory review. Commentators including Derek Lowe have questioned whether computational systems address the most difficult portion of drug development, especially work involving humans. XtalPi’s history therefore reflects both the growth of AI-enabled biotechnology and the continuing importance of experimental and clinical validation.
- 2025
Proposed share placement and industrial consortium
[1]The company announced a proposed HK$2.08 billion share placement and a Greater Bay Area project involving Hengjian Holding.
- 2024
Hong Kong initial public offering
[1]XtalPi listed on the Hong Kong Stock Exchange under the specialist-technology-company framework and reportedly raised HK$989.3 million.
- 2022
Expansion into materials science
[1]XtalPi began expanding its technology applications into areas such as photovoltaic and electric-vehicle battery materials.
- 2020
COVID-19 drug-discovery support
[1]XtalPi contributed to work associated with the development of Pfizer’s oral COVID-19 antiviral Paxlovid.
- 2016
Pfizer blind-test collaboration
[1]XtalPi participated in a Pfizer blind test involving three-dimensional molecular-structure prediction and was reported to have achieved complete accuracy.
- 2015
XtalPi is founded
[1]Wen Shuhao, Ma Jian and Lai Lipeng founded XtalPi in China to apply quantum-physics-based computation and machine learning to drug discovery.
Products and positioning
A technology and research partner for pharmaceutical and advanced-materials companies, combining AI, quantum computation, high-performance computing and laboratory automation to accelerate early-stage discovery.
Drug discovery technology
AI drug-discovery platform
XtalPi’s AI drug-discovery systems combine quantum-chemistry calculations, machine learning, high-performance computing and automated experiments. They are designed to search large molecular spaces, predict molecular properties, prioritize compounds and support customer research programs during the early discovery stage. The platform is used as a research service and technology layer rather than as a complete replacement for laboratory, clinical or regulatory development.
Pharmaceutical modeling
Crystal-form prediction
Crystal-form prediction technology models the solid-state forms that a pharmaceutical compound may adopt. Such forms can affect stability, manufacturability, solubility and product performance. XtalPi uses computational methods to help pharmaceutical researchers identify and evaluate possible crystal forms earlier in development, reducing reliance on exclusively experimental searches.
Drug research software
ID4 intelligent drug-research platform
ID4 is described as an intelligent drug-research platform associated with XtalPi. It represents the company’s effort to integrate computational modeling, AI-assisted molecular design, screening and research workflow support into a unified environment for pharmaceutical discovery teams.
Materials science · 2022
Materials-discovery services
XtalPi applies its computational and experimental capabilities to materials problems outside pharmaceuticals. Reported areas include perovskite photovoltaic materials and materials for electric-vehicle batteries. The objective is to identify or improve materials with useful performance characteristics while shortening experimentation and commercialization cycles.
Controversies
Brand decisions
2025
Proposed capital raise and Greater Bay Area integration projectStrategyBackground
XtalPi sought additional capital and a stronger connection between AI technology and industrial applications.
Action taken
The company announced a proposed HK$2.08 billion share placement and said a subsidiary would cooperate with Hengjian Holding on an AI and technology industrial-integration consortium project.
Aftermath
The announcement positioned XtalPi for further investment in regional technology and industrial initiatives.
Proposed share placement. HK$2.08 billion proposed (February 2025)
2024
Complete Hong Kong listingOtherBackground
XtalPi pursued public-market financing as a specialist technology company.
Action taken
It completed an initial public offering on the Hong Kong Stock Exchange under the Chapter 18C framework.
Aftermath
The company became publicly listed and reportedly raised HK$989.3 million.
IPO proceeds. HK$989.3 million raised (June 2024 IPO)
2022
Expand from drug discovery into materials scienceStrategyBackground
XtalPi sought applications beyond pharmaceuticals, where materials development may have shorter commercialization cycles and avoids the clinical-trial complexity of medicines.
Action taken
The company expanded work involving photovoltaic materials, perovskites and electric-vehicle battery materials.
Aftermath
The move broadened XtalPi’s addressable market and led to reported commercial work with industrial materials companies.
Recent events
XtalPi announces collaboration with MARVEL-AI[3]
XtalPi announced a collaboration with MARVEL-AI, led by Singapore's A*STAR, to contribute AI, computational prediction, robotic experimentation and experimental feedback capabilities to advance materials discovery and industrial translation.
XtalPi Holdings releases 2026 interim results[4]
Reported:
XtalPi Holdings reported 2026 first-half revenue of RMB 393.6 million, down from RMB 517.1 million a year earlier, mainly due to a high base from a USD 51.0 million upfront licensing payment recognized in the prior-year period; excluding that effect, revenue grew 73.8% year on year. The group reported a net loss of RMB 224.9 million and an adjusted net loss of RMB 105.5 million, with R&D expenses up 66.0% year on year, and held cash of RMB 8,671.2 million as of June 30, 2026.
- Unconfirmed
XtalPi appoints Maria G. Belvisi as Chief Scientific Officer[4]
Reported:
XtalPi Holdings appointed Dr. Maria G. Belvisi as Chief Scientific Officer. Belvisi has over 30 years of drug discovery and academic leadership experience, including about ten years at AstraZeneca where she served as Senior Vice President of Respiratory and Immunology in biopharmaceuticals R&D.
- Unconfirmed
XtalPi and Dongyangguang Pharmaceutical sign strategic cooperation to form joint venture[4]
Reported:
XtalPi Holdings signed a strategic cooperation agreement with Dongyangguang Pharmaceutical; the two parties plan to establish a joint venture company and jointly build an AI plus robotics joint laboratory and a non-clinical drug large model, carrying out cooperation on underlying technology, new drug pipeline development and commercialization. Dongyangguang Pharmaceutical is expected to invest several hundred million yuan, with the two companies aiming to build an industry-leading AI drug R&D engine and achieve technology going global.
- Unconfirmed
XtalPi signs AI drug discovery strategic partnership worth over USD 400 million[4]
Reported:
XtalPi Holdings reached an AI drug discovery strategic partnership with an internationally known biopharmaceutical company with a rich pipeline and multiple commercialized products, with a potential total value of over USD 400 million. The two parties will jointly develop a Best-in-Class potential oral small molecule drug against a GPCR target; the partner will pay an upfront payment and bear all early R&D costs, while XtalPi will also receive preclinical, clinical and commercialization milestone payments and future sales royalties.
- Unconfirmed
XtalPi signs AI plus automation high-throughput tandem solar cell R&D strategic cooperation with JinkoSolar subsidiary[4]
Reported:
XtalPi Holdings signed a strategic cooperation agreement on AI plus automation high-throughput tandem solar cell R&D with a subsidiary of JinkoSolar. The two parties have established a joint venture company to jointly build the world's first fully closed-loop tandem cell intelligent manufacturing line integrating AI decision-making, robot execution and data feedback; the project is underway.
XtalPi launches Genius Agent scientific AI agent[5]
XtalPi (Jingta Technology) introduced its Genius Agent scientific AI agent at a dedicated promotion event held on August 11, 2026 at the Hetao Sci-Tech Innovation Center in Shenzhen, co-hosted with the Shenzhen Development and Reform Commission. The agent acts as a scheduling hub that connects digital hypotheses, professional predictions, physical verification and data feedback, turning XtalPi's internal algorithms, models and robotic lab capabilities into scientific intelligence infrastructure available to external research organizations.
XtalPi launches XtalPi Science platform and Genius Agent matrix[4]
Reported:
In July 2026, XtalPi Holdings launched the XtalPi Science scientific intelligence platform and the Genius Agent scientific agent matrix. XtalPi Science is described as the world's first AI4S integrated platform combining large language models, scientific agents and large-scale automated robotic experiments, standardizing and platformizing the group's integrated research infrastructure into an on-demand, continuously extensible platform capability. The group also jointly initiated a Scientific Intelligence Open Ecosystem Alliance with 26 partners.
XtalPi and Chia Tai Tianqing announce drug-development partnership[6]
Reported:
XtalPi and Chia Tai Tianqing announced a strategic collaboration to jointly develop small-molecule drugs against difficult targets for cancer treatment. XtalPi will use its AI and computational chemistry platforms for compound generation, evaluation and optimization.
Leman Biotech completes nearly RMB 100 million angel funding[7]
Reported:
Leman Biotech announced on January 18 that it had completed an angel funding round of nearly RMB 100 million, led by Tiantu Capital, with 5Y Capital and XtalPi also investing. The funding is intended to advance preclinical research and drug-candidate development, among other stated uses.
Showing the 10 most recent.
Sources8 sources
Cite this profile: Cite the canonical profile. /brand-wiki/xtalpi · Editorial policy · How profiles are compiled